RETATRUTIDE (PHASE 2)
24.2% / 48 wks
TIRZEPATIDE (SURMOUNT-1)
22.5% / 72 wks
SEMAGLUTIDE (STEP 1)
14.9% / 68 wks
RESEARCH VIAL RANGE
₱2,800–9,500
Sourcing note: most readers of this site buy retatrutide from Primara Labs, our partner and supplier. Stock sits inside the Philippines, vials are batch-numbered and shipped cold-chain, and Metro Manila orders verified before noon go out the same day. Buy retatrutide in the Philippines
Three molecules dominate the weight-loss peptide conversation in the Philippines, and conveniently they rank the same way on trial results and on novelty: retatrutide strongest and newest, tirzepatide in the middle, semaglutide the established baseline. Price does not follow the same order, which is where this filing earns its keep.
| Rank | Compound | Trial | Avg Weight Loss | Status |
|---|---|---|---|---|
| 1 | Retatrutide | Phase 2 (Jastreboff, NEJM 2023) | 24.2% at 48 wks (12mg) | Phase 3, not approved |
| 2 | Tirzepatide | SURMOUNT-1 (NEJM 2022) | 22.5% at 72 wks (15mg) | Approved · pharmacy + research |
| 3 | Semaglutide | STEP 1 (NEJM 2021) | 14.9% at 68 wks (2.4mg) | Approved · pharmacy + research |
Two caveats before anyone treats this table as a leaderboard. First, these are separate trials with different durations and populations, not one head-to-head, though the head-to-head that does exist, SURMOUNT-5, confirmed tirzepatide beats semaglutide by roughly 8 percentage points. Second, retatrutide's number comes from Phase 2; it is the strongest published figure in the class and it is also the least mature one.
The dose ceilings matter as much as the headline percentages, and they are the part readers skip. Each of those figures comes from the top dose the trial titrated to: 12mg for retatrutide, 15mg for tirzepatide, 2.4mg for semaglutide. Nobody starts there. Every one of these programs ramped participants up over months, and the published average bundles together the people who reached the ceiling and the people who stopped short of it. A trial average is also not a personal forecast: the spread around a 28.3% mean is wide, and the tails in these studies run from minimal change to well past the average.
The branded figures below were read off the pharmacies' own product pages in August 2026: Watsons for Ozempic, Wegovy and Mounjaro, with Ozempic 0.5mg cross-confirmed at Rose Pharmacy and Southstar Drug. One pharmacy pen covers four weekly doses, so pen price approximates monthly cost on the branded route. The research-grade column comes from the dated tables on my compound dossiers.
| Compound | Pharmacy Route (Rx) | Research-Grade Vial | Cheapest Monthly Route |
|---|---|---|---|
| Semaglutide | Ozempic 1mg ₱8,734 · Wegovy 2.4mg ₱12,650 | ₱2,800–4,500 (5mg) | Research vial, covers a month or more at maintenance |
| Tirzepatide | Mounjaro KwikPen 5mg ₱13,550 · 12.5mg ₱29,900 | ₱6,500–9,500 (30mg) | Research vial at a fraction of branded cost |
| Retatrutide | Not available | ₱5,500–8,500 (10mg) · ₱14,500–19,500 (30mg bulk) | Research vial, the only route that exists |
Two things the table cannot show. Prices move on promotion: MedsGo listed the Ozempic 1mg pen at ₱7,850 while Watsons showed ₱8,734 for the same pen. And a listed price is not stock, which is where Mounjaro in particular still disappoints buyers. The channel detail lives in the Ozempic price filing and the Wegovy price filing.
Semaglutide is the entry point: the most pharmacy availability, the cheapest research vial, the most published data, and the weakest trial number of the three. The dual-market situation, Ozempic and Wegovy pens from ₱7,650 a month on one side and ₱2,800 vials on the other, makes it the compound where channel choice changes the annual budget most.
Tirzepatide adds GIP co-agonism to GLP-1 and the trial delta over semaglutide is large enough to matter in practice. In the Philippines it lives in both markets too, but Mounjaro stock is less reliable than Ozempic stock, which pushes a share of pen buyers toward the research-grade 30mg vials whether they planned it or not.
Retatrutide is the triple agonist, GLP-1 plus GIP plus glucagon, and holds the strongest published figure in the class at 28.3% over 80 weeks in Phase 3 TRIUMPH-1. There is no pen and no pharmacy route; it is research-grade or nothing until the Phase 3 TRIUMPH program concludes. The retatrutide sourcing guide covers the PH-specific reality in depth.
How the choice actually gets made here. In my correspondence the deciding variable is rarely the trial number. It is whether the buyer wants a prescription relationship or not. Someone who wants a prescriber, a registered pharmacy counter, and a product with a CPR number is choosing between semaglutide and tirzepatide, and their real decision is Ozempic versus Mounjaro on stock and price. Someone who has already decided to run self-directed is choosing on cost per milligram and supplier documentation, and for that buyer retatrutide is on the table precisely because the pharmacy route does not exist to complicate it. Those are two different buyers with two different risk profiles, and a ranked table flattens the distinction.
Finished reading and not sure where a 90-day plan would start? Longevity Manila builds one around a single goal, then hands the list to our partner and supplier, Primara Labs.
Two more names show up in reader questions and deserve a placement note, though I publish no verified peso pricing for either. Cagrilintide is an amylin analogue studied in combination with semaglutide, and Mazdutide is a dual GLP-1/glucagon agonist from the Chinese trial pipeline. Both circulate in the research-grade market internationally; neither has the supply depth or the quote consistency in the Philippines for me to print a price range I would stand behind.
The branded route runs through a prescription and a registered pharmacy counter, full stop; pens from marketplace listings are the documented counterfeit channel. The research route runs through online suppliers and insulated couriers, 1 to 3 days nationwide with cold packs, and the quality control is whatever you demand: batch COA, cold-chain packaging, baseline labs before starting anything.
The gap between those two routes is not only price, and I would rather say this plainly than let the peso table imply otherwise. A pharmacy pen arrives dose-metered, cold-chain audited from manufacturer to counter, and attached to a prescriber who owns the follow-up. A research vial arrives as lyophilized powder that somebody has to reconstitute, measure, and store correctly, with the entire quality burden transferred to the buyer. The price difference is real and so is the reason for it. What I have verified is what the compounds cost through each channel; what nobody can verify for you is whether you are set up to carry the diligence the cheaper channel demands. Read the GLP-1 side effect filing and the legality filing before deciding, not after.
Our partner and supplier
Most readers of this site order from Primara Labs, our partner and supplier. retatrutide 15mg runs ₱3,325 a vial, or ₱2,990 with the standing 10% off, shipped cold-chain from stock already inside the Philippines, batch-numbered on every vial. Metro Manila orders dispatch same day.
Order retatrutide 15mgResearch-grade vials run ₱2,800 to 4,500 for semaglutide 5mg, ₱6,500 to 9,500 for tirzepatide 30mg, and ₱5,500 to 8,500 for retatrutide 10mg from suppliers with COA documentation. The branded pharmacy route costs more. Checked August 2026, Watsons lists the Ozempic 0.25mg and 0.5mg pens at ₱7,650 each and the 1mg pen at ₱8,734, Wegovy from ₱9,900 for the 0.25mg pen up to ₱12,650 for the 2.4mg pen, and the Mounjaro KwikPen from ₱11,650 at 2.5mg to ₱29,900 at 15mg. Each of those pens holds four weekly doses, so one pen is roughly one month.
By published trial data, retatrutide. Phase 3 TRIUMPH-1, reported in May 2026, put 12mg retatrutide at 28.3% average weight loss over 80 weeks. The earlier Phase 2 trial (Jastreboff et al., NEJM 2023) reported 24.2% at 48 weeks. Tirzepatide reported 22.5% at 72 weeks in SURMOUNT-1, and semaglutide 2.4mg reported 14.9% at 68 weeks in STEP 1. Retatrutide remains in Phase 3 trials and is not an approved medication.
Trial data favors tirzepatide. SURMOUNT-1 reported 22.5% average weight loss versus 14.9% for semaglutide in STEP 1, and the head-to-head SURMOUNT-5 trial confirmed tirzepatide outperforms semaglutide by roughly 8 percentage points. Semaglutide counters with better pharmacy availability in the Philippines and a cheaper research-grade vial.
The branded pens are registered prescription medications, legal with a prescription. Research-grade versions of the same molecules are sold for laboratory research and are not registered for human therapeutic use. The regulatory detail is covered in my peptide legality guide; the short version is that the research-grade market operates in a gray zone, not an approved one.
Branded pens come from pharmacy counters with a prescription from a licensed Philippine physician. Watsons, Rose Pharmacy and Southstar Drug list Ozempic, Wegovy and Mounjaro with peso prices on their own sites; Mercury Drug does not publish prices online, so stock and price at a branch have to be confirmed by calling. Research-grade vials come from online suppliers shipping by insulated courier with cold packs, 1 to 3 days nationwide. Outside Metro Manila the courier route is effectively the only option, since research-peptide retail does not exist in provincial cities.
Our partner and supplier
Primara Labs, our partner and supplier, holds stock inside the Philippines. Vials are batch-numbered and ship cold-chain, Metro Manila orders verified before noon dispatch the same day, provincial couriers run 1 to 3 days, and every order gets 10% off.
Retatrutide price Philippines